Lung & Respiratory Breakthroughs: RSV Protection, STAT6 Alternatives, and Full CFTR Correction 🫁💊
This week on Lung and Respiratory Health Updates, we’re spotlighting nine cutting-edge developments transforming the future of respiratory care—from once-daily inhalables for pulmonary hypertension to the first-ever oral STAT6 inhibitor challenging dupilumab. Whether you’re a biotech leader, clinician, or investor, this is your weekly edge on emerging therapies and trials.
💉 Mediar Launches Phase 2 Trial Targeting WISP1 in IPF
🧪 Oxcia’s Dual Pipeline Shows Anti-Inflammatory Promise in Asthma
🫁 Vertex’s ALYFTREK Surpasses TRIKAFTA in CF Function & Quality of Life
🔬 Sionna’s CFTR Modulator Combos Deliver Wild-Type Correction in Models
🌿 PIMS Launches MICU, Integrates Benralizumab for Severe Asthma
👶 FDA Approves ENFLONSIA for RSV Prevention in Infants
🚶 Insmed’s TPIP Meets All Phase 2b Endpoints in PAH
🧬 Gyre Starts First-in-Human Trial of ETA Antagonist F230 for PAH
💊 DeepCure Develops Oral STAT6 Inhibitor as Biologic-Free Alternative
📢 Stay Ahead in Lung and Respiratory Research!
✅ Like, share, and subscribe for weekly updates on lung and respiratory research
#LungHealth #RespiratoryInnovation #CFResearch #AsthmaTreatment #IPF #RSVPrevention #PulmonaryHypertension #STAT6 #Benralizumab #CFTR #FDAApproval #OralBiologics #Vertex #SionnaTx #Insmed #DeepCure #GyreTx #MerckRSV #Oxcia #LucidQuestHealth #ClinicalTrials #BiotechNews #RespiratoryCare